Bayforest Capital Ltd Increases Stock Position in Humana Inc. (NYSE:HUM)

Key Points

• Bayforest Capital Ltd significantly increased its holdings in Humana Inc. by 803.1%, acquiring an additional 3,927 shares to own a total of 4,416 shares, valued at approximately $1.17 million.
• Humana reported earnings of $11.58 per share for the previous quarter, exceeding analyst expectations by $1.51, and generated revenues of $32.11 billion.
• The stock has a current market cap of $28.07 billion with a price-to-earnings ratio of 16.45, indicating solid performance despite a 52-week range between $206.87 and $406.09.

Bayforest Capital Ltd raised its position in Humana Inc. (NYSE:HUM - Free Report) by 803.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,416 shares of the insurance provider's stock after acquiring an additional 3,927 shares during the quarter. Humana makes up about 0.6% of Bayforest Capital Ltd's holdings, making the stock its 16th biggest holding. Bayforest Capital Ltd's holdings in Humana were worth $1,168,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. S&CO Inc. raised its position in Humana by 7.2% in the 1st quarter. S&CO Inc. now owns 22,696 shares of the insurance provider's stock valued at $6,005,000 after purchasing an additional 1,528 shares during the last quarter. Banque Cantonale Vaudoise acquired a new position in shares of Humana during the 1st quarter worth $2,308,000. High Ground Investment Management LLP grew its stake in Humana by 1.4% in the 1st quarter. High Ground Investment Management LLP now owns 430,498 shares of the insurance provider's stock valued at $113,910,000 after acquiring an additional 6,095 shares during the last quarter. Federated Hermes Inc. grew its stake in Humana by 6.3% in the 1st quarter. Federated Hermes Inc. now owns 83,276 shares of the insurance provider's stock valued at $22,035,000 after acquiring an additional 4,919 shares during the last quarter. Finally, N.E.W. Advisory Services LLC acquired a new stake in Humana in the 1st quarter valued at about $144,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Stock Performance

Shares of NYSE:HUM traded down $2.68 during trading on Friday, hitting $247.19. 1,756,006 shares of the company were exchanged, compared to its average volume of 1,854,830. The company has a market cap of $29.73 billion, a PE ratio of 18.97, a P/E/G ratio of 1.66 and a beta of 0.44. The stock has a 50 day moving average of $234.64 and a 200 day moving average of $255.48. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $382.72. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.91.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The firm had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the company earned $6.96 EPS. As a group, equities research analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on HUM shares. Truist Financial reduced their target price on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Piper Sandler reduced their target price on shares of Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a report on Thursday. Guggenheim initiated coverage on shares of Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 price objective on the stock. Morgan Stanley cut their price objective on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a report on Thursday. Finally, Wall Street Zen upgraded shares of Humana from a "hold" rating to a "buy" rating in a report on Sunday, July 20th. Sixteen analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $281.62.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.